Unproven Stem Cell Therapies to Be Scrutinized by House Panel

Aug. 29, 2017, 2:02 PM

A House panel will look this fall at companies peddling unproven and sometimes dangerous stem cell treatments as part of a broader focus on a major biomedical innovation law.

“Advancing the field of regenerative medicine is a critical component in the 21st Century Cures Act (Pub. 114-255) and the committee looks forward to examining it, as well as the various other components within the law, in the coming months during implementation,” a spokeswoman for the House Energy and Commerce Committee told Bloomberg BNA in an Aug. 28 email.

The committee has not scheduled any formal hearings ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.